TSH Prevents Bone Resorption and with Calcitriol Synergistically Stimulates Bone Formation in Rats with Low Levels of Calciotropic Hormones

I. Dumic-Cule; N. Draca; A. T. Luetic; D. Jezek; D. Rogic; L. Grgurevic; S. Vukicevic

doi:10.1055/s-0033-1363989

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2014; 46(05): 305-312
DOI: 10.1055/s-0033-1363989

Endocrine Research

TSH Prevents Bone Resorption and with Calcitriol Synergistically Stimulates Bone Formation in Rats with Low Levels of Calciotropic Hormones

I. Dumic-Cule

¹Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia

,

N. Draca

¹Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia

,

A. T. Luetic

¹Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia

,

D. Jezek

²Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia

,

D. Rogic

³Clinical Institute of Laboratory Diagnosis, University Hospital Centre Zagreb, Zagreb, Croatia

,

L. Grgurevic

¹Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia

,

S. Vukicevic

¹Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Zagreb, Croatia

› Institutsangaben

Abstract

Thyroid-stimulating hormone exerts both antiresorptive and anabolic effects on bone remodeling in aged ovariectomized rats and thyroid stimulating hormone-receptor null mice, supported by clinical results demonstrating that low thyroid-stimulating hormone level is associated with increased bone loss. To further explore the effect of thyroid-stimulating hormone on bone metabolism we introduced here a rat model with removed thyroid and parathyroid glands to obtain low serum concentrations of thyroid and parathyroid hormone, calcitonin and 1,25(OH)₂D₃. Surgery resulted in hypocalcemia, low parathyroid and thyroid hormone, 1,25(OH)₂D₃, C-telopeptide, and osteocalcin serum level. Intermittent administration of thyroid-stimulating hormone resulted in a further decrease of serum calcium and decreased level of serum C-telopeptide due to the suppression of bone resorption, while in the same animals osteocalcin in serum was higher indicating an increased bone formation rate. A combination of thyroid-stimulating hormone and 1,25(OH)₂D₃ significantly increased the serum Ca²⁺, C-telopeptide and serum osteocalcin values. MicroCT analyses of the distal femur and proximal tibia showed that rats treated with 1,25(OH)₂D₃ alone or in a combination with thyroid-stimulating hormone had an increased trabecular bone volume, and enhanced trabecular bone quality. Biomechanical testing of the trabecular bone showed an increased maximal load for 105% and 235%, respectively, in rats treated with 1,25(OH)₂D₃ alone, or in a combination with thyroid-stimulating hormone. We suggest that thyroid-stimulating hormone independently of calciotropic hormones suppressed bone resorption and stimulated bone formation, while in combination with 1,25(OH)₂D₃ acted synergistically on bone formation resulting in an increased bone volume.

Key words

thyroid hormones - bone mineral density - osteoblast

Volltext

Referenzen

References
1 Postiglione MP, Parlato R, Rodriguez-Mallon A, Rosica A, Mithbaokar P, Maresca M, Marians RC, Davies TF, Zanini MS, DeFelice M, DiLauro R. Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. Proc Natl Acad Sci USA 2002; 99: 15462-15467
2 Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest 2002; 110: 161-164
3 Williams GR. Extrathyroidal expression of TSH receptor. Ann Endocrinol (Paris) 2011; 72: 68-73
4 de Lloyd A, Bursell J, Gregory JW, Rees DA, Ludgate M. TSH receptor activation and body composition. J Endocrinol 2010; 204: 13-20
5 Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-162
6 Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys 2010; 503: 129-136
7 Zaidi M, Davies TF, Zallone A, Blair HC, Iqbal J, Moonga SS, Mechanick J, Sun L. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 2009; 7: 47-52
8 Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E. TNFα mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci USA 2006; 103: 12849-12854
9 Sun L, Davies TF, Blair HC, Abe E, Zaidi M. TSH and bone loss. Ann N Y Acad Sci 2006; 1068: 309-318
10 Baqi L, Payer J, Killinger Z, Hruzikova P, Cierny D, Susienkova K, Langer P. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women. Endocr Regul 2010; 44: 57-63
11 Bauer DC, Ettinger B, Nevitt MC, Stone KL. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001; 134: 561-568
12 Ongphipliadhandiul B, Puavilai G, Rajatanavin R. Effect of TSH-suppresive doses of levothyroxine on bone mineral density in Thai women. J Med Assoc Thai 1996; 79: 563-567
13 Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. Thyroid 2008; 18: 1147-1155
14 Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrionol(Oxf) 2004; 61: 285-298
15 Nicholls JJ, Brassill MJ, Williams GR, Basset JH. The skeletal consequences of thyrotoxicosis. J Endocrinol 2012; 213: 209-221
16 Williams GR. Actions of thyroid hormones in bone. Endokrynol Pol 2009; 60: 380-388
17 Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O’Brien S, Schiavi SC, McPherson JM, Vukicevic S. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 2007; 22: 849-859
18 Guo YD, Strugnell S, Back DW, Jones G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc Natl Acad Sci USA 1993; 90: 8668-7862
19 Turner CH, Burr DB. Basic biomechanical measurements of bone: A tutorial. Bone 1993; 14: 595-608
20 Kim BJ, Lee SH, Bae SJ, Kim HK, Choe JW, Kim HY, Koh JM, Kim GS. The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. Clin Endocrinol(Oxf) 2010; 73: 396-403
21 Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A. SERUM TSH values and risk of vertebral fractures in euthyroid postmenopausal women with low bone mineral density. Bone 2010; 46: 747-751
22 Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, Chen Z, Cauley J, Bauer DC, Cappola AK, Robbins J. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010; 170: 1876-1883
23 Baliram R, Sun L, Cao J, Li J, Latif R, Huber AK, Yuen T, Blair HC, Zaidi H, Davies TF. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 2012; 122: 3737-3741
24 Ma R, Morshed S, Latif R, Zaidi M, Davies TF. The influence of thyroid-stimulating hormone and thyroid-stimulationg hormone receptor antibodies on osteoclastogenesis. Thyroid 2011; 21: 897-906
25 Raggatt LJ, Patridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem 2010; 285: 25103-25108
26 Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hara M, Feng JQ, Bonewald LF, Kodima T, Wutz A, Wagner EF, Penninger JM, Takayanaga H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17: 1231-1234
27 Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Schully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176
28 Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275: 4858-4864
29 Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488
30 Hase H, Audo T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci USA 2006; 103: 12849-12854
31 Norman AW. Bone biochemistry and physiology from the perspectives of the vitamin D endocrine system. Curr Opin Rheumatol 1992; 4: 375-382
32 Baliram R, Latif R, Berkowitz J, Frid S, Colaianni G, Sun L, Zaidi H, Davies TF. Thyroid-stimulating hormone induces Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures. Proc Natl Acad Sci USA 2011; 108: 16277-16282
33 Bassett JH, Boyde A, Howell PG, Basset RH, Galliford TM, Archanco H, Evans H, Lawson MA, Groucher P, StGermain DL, Galton VA, Williams GR. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. Proc Natl Acad Sci USA 2010; 107: 7604-7609
34 Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M, Murakami M. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005; 146: 2077-2084